Levofloxacin: Insights Into Antibiotic Resistance and Product Quality
Open Access
- 14 August 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 10, 881
Abstract
Counterfeit and substandard medicines are recognized as one of serious threats to public health. The product quality of antibacterial medicine will compromise patients' recovery and increase the chance of antibacterial resistance. The review aims to provide a summary of low quality levofloxacin issues and the risk factors as well as suggesting the aspects of product quality that need to be regulated strictly. Quality of the active ingredient, levofloxacin, has an important role to contribute to successful therapy. The poor quality of raw material, directly and indirectly, causes treatment failure as the presence of insufficient dose, mislabeled content, and poor dissolution characteristics can lead to lower bioavailability. Identifying and reporting these factors can potentially help in improving the quality of drug marketed in various developing countries and may also reduce the incidences of treatment failure. Dissolution test is used for testing the dissolution profiles and the rate of drug release from solid formulation such as oral formulations, thus providing information regarding the in vivo performance of a formulation and its bioequivalence. On the other hand, quality-testing procedures are used for comparing the quality of products.Keywords
This publication has 68 references indexed in Scilit:
- Substandard and counterfeit medicines: a systematic review of the literatureBMJ Open, 2013
- A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case studyBMC Pharmacology and Toxicology, 2013
- Dissolution Testing for Generic Drugs: An FDA PerspectiveThe AAPS Journal, 2011
- General Principles of Antimicrobial TherapyMayo Clinic Proceedings, 2011
- Good Manufacturing Practice: The Role of Local Manufacturers and Competent AuthoritiesArchives of Industrial Hygiene and Toxicology, 2010
- Impact of poor-quality medicines in the ‘developing’ worldTrends in Pharmacological Sciences, 2010
- Relationships among Ciprofloxacin, Gatifloxacin, Levofloxacin, and Norfloxacin MICs for Fluoroquinolone-Resistant Escherichia coli Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2009
- Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular DiseaseJAMA, 2008
- Substandard anti-malarial drugs in Burkina FasoMalaria Journal, 2008
- Adverse reaction reports may be vulnerable to manipulationBMJ, 2005